Logo image of SLNO

SOLENO THERAPEUTICS INC (SLNO) Stock Overview

USA - NASDAQ:SLNO - US8342033094 - Common Stock

63.045 USD
-1.45 (-2.26%)
Last: 9/25/2025, 3:07:21 PM

SLNO Key Statistics, Chart & Performance

Key Statistics
52 Week High90.32
52 Week Low41.5
Market Cap3.35B
Shares53.15M
Float51.75M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-4.14
PEN/A
Fwd PE23.64
Earnings (Next)11-04 2025-11-04/amc
IPO10-23 2014-10-23
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


SLNO short term performance overview.The bars show the price performance of SLNO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 -20

SLNO long term performance overview.The bars show the price performance of SLNO in the last 1, 2 and 3 years. 1 year 2 years 3 years 1K 2K 3K

The current stock price of SLNO is 63.045 USD. In the past month the price decreased by -7.34%. In the past year, price increased by 31.28%.

SOLENO THERAPEUTICS INC / SLNO Daily stock chart

SLNO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.69 387.14B
AMGN AMGEN INC 12.44 146.11B
GILD GILEAD SCIENCES INC 14.41 138.35B
VRTX VERTEX PHARMACEUTICALS INC 22.52 97.83B
REGN REGENERON PHARMACEUTICALS 12.18 58.92B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.63B
ARGX ARGENX SE - ADR 76.53 43.41B
ONC BEONE MEDICINES LTD-ADR 5.73 38.94B
INSM INSMED INC N/A 28.72B
BNTX BIONTECH SE-ADR N/A 23.59B
NTRA NATERA INC N/A 22.35B
BIIB BIOGEN INC 8.5 19.96B

About SLNO

Company Profile

SLNO logo image Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is headquartered in Redwood City, California and currently employs 133 full-time employees. The company went IPO on 2014-10-23. The firm is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The firm has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.

Company Info

SOLENO THERAPEUTICS INC

100 Marine Parkway, Suite 400

Redwood City CALIFORNIA 94065 US

CEO: Anish Bhatnagar

Employees: 92

SLNO Company Website

SLNO Investor Relations

Phone: 16502138444

SOLENO THERAPEUTICS INC / SLNO FAQ

What is the stock price of SOLENO THERAPEUTICS INC today?

The current stock price of SLNO is 63.045 USD. The price decreased by -2.26% in the last trading session.


What is the ticker symbol for SOLENO THERAPEUTICS INC stock?

The exchange symbol of SOLENO THERAPEUTICS INC is SLNO and it is listed on the Nasdaq exchange.


On which exchange is SLNO stock listed?

SLNO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for SOLENO THERAPEUTICS INC stock?

16 analysts have analysed SLNO and the average price target is 120.97 USD. This implies a price increase of 91.88% is expected in the next year compared to the current price of 63.045. Check the SOLENO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is SOLENO THERAPEUTICS INC worth?

SOLENO THERAPEUTICS INC (SLNO) has a market capitalization of 3.35B USD. This makes SLNO a Mid Cap stock.


How many employees does SOLENO THERAPEUTICS INC have?

SOLENO THERAPEUTICS INC (SLNO) currently has 92 employees.


What are the support and resistance levels for SOLENO THERAPEUTICS INC (SLNO) stock?

SOLENO THERAPEUTICS INC (SLNO) has a support level at 55.15 and a resistance level at 71.9. Check the full technical report for a detailed analysis of SLNO support and resistance levels.


Should I buy SOLENO THERAPEUTICS INC (SLNO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does SOLENO THERAPEUTICS INC (SLNO) stock pay dividends?

SLNO does not pay a dividend.


When does SOLENO THERAPEUTICS INC (SLNO) report earnings?

SOLENO THERAPEUTICS INC (SLNO) will report earnings on 2025-11-04, after the market close.


What is the Price/Earnings (PE) ratio of SOLENO THERAPEUTICS INC (SLNO)?

SOLENO THERAPEUTICS INC (SLNO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.14).


What is the Short Interest ratio of SOLENO THERAPEUTICS INC (SLNO) stock?

The outstanding short interest for SOLENO THERAPEUTICS INC (SLNO) is 14.65% of its float. Check the ownership tab for more information on the SLNO short interest.


SLNO Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to SLNO. When comparing the yearly performance of all stocks, SLNO turns out to be only a medium performer in the overall market: it outperformed 51.21% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

SLNO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to SLNO. SLNO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SLNO Financial Highlights

Over the last trailing twelve months SLNO reported a non-GAAP Earnings per Share(EPS) of -4.14. The EPS decreased by -69.67% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -54.49%
ROE -75.41%
Debt/Equity 0.21
Chartmill High Growth Momentum
EPS Q2Q%84.21%
Sales Q2Q%N/A
EPS 1Y (TTM)-69.67%
Revenue 1Y (TTM)N/A

SLNO Forecast & Estimates

16 analysts have analysed SLNO and the average price target is 120.97 USD. This implies a price increase of 91.88% is expected in the next year compared to the current price of 63.045.


Analysts
Analysts86.25
Price Target120.97 (91.88%)
EPS Next Y75.22%
Revenue Next YearN/A

SLNO Ownership

Ownership
Inst Owners105.59%
Ins Owners1.45%
Short Float %14.65%
Short Ratio4.54